Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.40p -0.37% 374.70p 374.90p 375.10p 376.80p 371.10p 376.80p 285,977 10:09:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 688.2 193.4 21.7 15.5 2,701.54

Indivior Share Discussion Threads

Showing 351 to 373 of 375 messages
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
DateSubjectAuthorDiscuss
08/11/2017
09:43
Citibank upped its recommendation apparently. Maybe caught a few on the hop.
gregmorg
04/11/2017
16:59
I've only just taken a small holding here, it was going to be a day trade flip but upon looking at the near and long term horizon I have decided to give this the time for growth that it deserves. Smack is huge in Murca!
cmackay
03/11/2017
08:31
Mercurial!
steeplejack
02/11/2017
09:23
Agreed. That scenario is certainly possible. Liked the Lex article . There were a lot of negative comments from the Advisory panel on this possible rival product so we shall see what the FDA actually decide.. Even the final positive vote for just some of that company's doses surprised me. What came through from the speakers/panel was the alarm being created throughout the USA by the opioid crisis. As an aside and referring back to the Indivior product there was a strange reference to one individual's adverse reaction to Bup 6000. That comment under adverse reactions was "death by gunshot!" That adverse reaction was then described as not unusual in that world! To have set that tragic incident down to an adverse reaction seemed bizarre although obviously that person didn't actually complete the trial!
gregmorg
02/11/2017
08:31
CAM2038......Interesting.Yes it seems unlikely Greg that it's going to get the same 'clean bill of health' that RBP-6000 received,in fact Alphaville even suggested that some reckon that a launch of CAM2038 might be delayed for a couple of years giving RBP-6000 a real advantage of building up sales without this competitor cantering alongside.Mind you,given the opioid crisis in the US,I reckon it'll be approved and launch is expected in January next year.
steeplejack
02/11/2017
08:04
We wait on the results to be announced at 11amLEX concluded yesterday ,......."Nor will demand for Suboxone, shown by a 9 per cent jump in Indivior shares. Having retraced almost all of September's fall, they should go higher".
steeplejack
01/11/2017
21:01
Just could be a slight share price easing tomorrow prior to the figures/meeting. Another US company had its inject able product was up before the same FDA Committee tonight. Unlike Indivior with a clean approvals sheet, Camurus/Braeburn got a qualified approval for its CAM2038 but for only some of its proposed doses. The vote was 17 to 3 with the latter 3 indicating NO approval for any of the doses. This product approval process was known about and indeed discussed in a market column of the FT around 11am today. Just not in a position to evaluate the merits of the other product. We will hear what Indivior has to say tomorrow.
gregmorg
01/11/2017
13:18
I understand a couple of brokers have increased their price target- not that that's anything other than a guide to investor sentiment. Both with a share price figure higher than where we are now. Numis has a high figure as follows : " This recommendation for approval significantly de-risks the longer-term investment case, and our target price thus increases to 640p, based on de-risking future cash-flow due to a more normalised discount rate and the assumption of generic film in 2018."
gregmorg
01/11/2017
11:47
Yup, as you say, who knows with this one! Good thing is it is increasingly looking a less dangerous/more secure company. So after the 2nd November we then roll on to that other tester of our investors steel --on the 14th. Will see how that coding scenario has developed . It could be the stock starts to put the days of serious uncertainty behind it. Revenues are looking good and growing very respectably. But what about the veins!~! Thinking of patience(or apathy!) I have been a little puzzled by GSK's share price performance in recent time but am hoping this baptism of fire gears up/fires up the new CEO. OR what! As for my other pharma, IMB, I do wish, Steeplejack, I had more noted your disposal some months back and so questioned my own rationale. Good call. Now I am left waiting for Vaping to kick in! Hopefully this is made less painless by a continued good stream of dividends. Let's see what tomorrow brings on IND . Unfortunately I cannot listen in to the live investors meeting as I have some silly cross country trail commitment. Hopefully I can listen in later in the day.
gregmorg
01/11/2017
08:50
Excellent news.Well done Greg.Extraordinary looking chart.I suppose it's back to litigation for the next plummet or spike,who knows.
steeplejack
01/11/2017
08:35
Brilliant rise in 2 months. 267 to 414. I have to cash in on this now.
sarpanch
01/11/2017
08:31
🤡✌A039; wow! What a turnaround!
glenkaz
31/10/2017
21:06
Steeplejack. I understand the Committee vote at the end was 18 for and one against.The latter was on the basis of this was nothing new! This, I hasten to add, is purely my understanding. I did say this Committee is advisory but it does look as if the recommendation to the FDA is going our way. A few concerns were raised re the results of the 300mg doses( as opposed to the 100mg) and a few small issues that resulted, but this does not appear to have affected the outcome. So possibly it is looking OK!. We both have experiences of erratic share price performance across the financial reporting period so its important to maintain the longer view.
gregmorg
30/10/2017
22:50
Thanks Steeplejack. Trouble is it is a weighty document with over 100 pages, many technical, and a heavyweight panel. I understand its relatively positive but that is just one person's interpretation after a quick scan. It's headed FDA Briefing Document Joint Meeting of Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee October 31, 2017 RE: Overview of the October 31, 2017 PDAC/DSARM Joint Meeting on NDA 209819 for RBP-6000 (buprenorphine injectable) for treatment of opioid dependence
gregmorg
30/10/2017
22:36
You're a mine of information,Greg!
steeplejack
30/10/2017
19:05
Yes, My understanding is Public Committee Meeting relating to the injectable. Committee only provides guidance to the FDA but it maybe weighty. So maybe some speculation results from that!
gregmorg
30/10/2017
18:10
Drug review tomorrow? Any thoughts?
sarpanch
18/10/2017
12:51
This was, of course, as reported by Reckitt some months ago!
gregmorg
18/10/2017
12:44
Extract from this mornings Reckitt Benckiser Trading Statement "Indivior / RB Pharma related matters: As noted in Note 9 of our Interim Statement 2017, the Group remains involved in ongoing investigations by the US Department of Justice (DoJ) and the US Federal Trade Commission and related litigation proceedings by certain state attorneys in the US arising from certain matters relating to the RB Pharmaceuticals (RBP) business prior to its demerger in December 2014 to form Indivior plc and may incur liabilities in relation to such matters. These investigations and related proceedings are continuing and we are in active discussions with the DoJ. As a consequence of these discussions, we recorded a charge of GBP318 million at 30 June 2017 within our discontinued operations line. The Group remains committed to ensuring these issues are concluded or resolved satisfactorily but we cannot predict with any certainty whether we will be able to reach any agreement with the DoJ or other parties who are involved in any other investigation or in the related proceedings. The final cost for the Group may be materially higher than this reserve."
gregmorg
12/10/2017
07:06
Indivior to Announce 2017 Third Quarter and Year-to-Date Results on November 2(nd)
steeplejack
12/10/2017
06:25
10 October 2017 Indivior to Announce 2017 Third Quarter and Year-to-Date Results on November 2(nd) Slough, UK, and Richmond, VA, 10 October 2017 - Indivior PLC (LON: INDV) today announced that it will release its 2017 third quarter and year-to-date results on November 2(nd) at 11:00 a.m. London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com. Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12 noon London time (8:00 a.m. U.S. Eastern) on November 2(nd) . Access the Live Webcast for the Results Call on November 2nd The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is hxxps://edge.media-server.com/m6/p/b6jz7h6i. Participants also may access the results presentation telephonically: US participants 1-646-254-3361; international participants 44(0)20-3427-1901. Please reference confirmation number 9592820. A replay of the presentation will be available at www.indivior.com. About Indivior Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Contact: Jason Thompson Vice President, Investor Relations Tel: 804-423-8916 or jason.thompson@indivior.com ### This information is provided by RNS The company news service from the London Stock Exchange END NOREAXENEEAXFFF (END) Dow Jones Newswires October 10, 2017 02:00 ET (06:00 GMT)
waldron
09/10/2017
13:50
Old Mutual have sold 2.65%(19.1m shares) of the equity bringing their holding down to 4.36%.Now we know where Scopia were acquiring their stock.
steeplejack
07/10/2017
07:35
Great stuff 🤡👍
glenkaz
Chat Pages: 15  14  13  12  11  10  9  8  7  6  5  4  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20171121 10:25:12